Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV)
To Determine Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy(PCV)
1 other identifier
observational
72
1 country
3
Brief Summary
To determine long-term outcomes, recurrence rates, and treatment needs in Polypoidal Choroidal Vasculopathy (PCV). Specifically, to describe the long-term outcomes, recurrence rates and treatment patterns PCV patients 5 years after first presentation. This study will also evaluate whether polyp closure within the first 12 months of therapy is associated with better long-term visual outcome and will also determine the risk of disease development in the fellow eye
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2019
Longer than P75 for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 24, 2019
CompletedFirst Posted
Study publicly available on registry
April 29, 2019
CompletedStudy Start
First participant enrolled
July 5, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 9, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 9, 2024
CompletedNovember 18, 2025
April 1, 2025
4.8 years
April 24, 2019
November 14, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Long term prognostication
Long term recurrence rates, correlated baseline characteristics and initial treatment strategies correlated to long term outcomes
within 72 months
Study Arms (1)
Polypoidal Choroidal Vasculopathy RCT
Participants will have completed the previous PCV RCTs: EVEREST II, PLANET and PCV T\&E studies
Interventions
Intravenous injection of dye-indocyanine green
Eligibility Criteria
Participants will have completed the previous PCV RCTs: EVEREST II, PLANET and PCV T\&E studies
You may qualify if:
- Participants will have completed the previous PCV RCTs: EVEREST II, PLANET and PCV T\&E studies
- Are able to give consent for this follow up study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
Singapore National Eye Centre
Singapore, Singapore, 168751, Singapore
Tan Tock Seng Hospital
Singapore, Singapore, 308433, Singapore
National University Hospital
Singapore, Singapore
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Principal Investigator
Singapore National Eye Centre
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 24, 2019
First Posted
April 29, 2019
Study Start
July 5, 2019
Primary Completion
May 9, 2024
Study Completion
May 9, 2024
Last Updated
November 18, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will not share